PTO/SB/21 (04-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Application Number	10/056,680
TRANSMITTAL	Filing Date	January 25, 2002
FORM	First Named Inventor	T. Kosoglou et al.
(to be used for all correspondence after initial fil	ing) Art Unit	1617
	Examiner Name	San-Ming R. Hui
Total Number of Pages in This Submission	Attorney Docket Number	(CV01492K US) 4686-045551

EN	ICLOSURES (Check all that apply)				
☐ Fee Transmittal Form	☐ Drawing(s)	☐ After Allowance communication To Technology Center (TC)			
☐ Fee Attached	☐ Licensing-related Papers				
☐ Amendment/Reply	☐ Petition to Reinstate	 Appeal Communication to Board Of Appeals and Interferences 			
☐ After Final	☐ Petition to Convert to a Provisional Application	☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)			
☐ Affidavits/declaration(s)					
☐ Extension of Time Request	☐ Power of Attorney, Revocation Change of Correspondence Address	☐ Proprietary Information			
·		□ Status Letter			
□ Express Abandonment Request	☐ Terminal Disclaimer	☑ Other Enclosure(s) (please			
☑ Information Disclosure Statement	□ Request for Refund	identify below)			
☐ Certified Copy of Priority Documents	□ CD, Number of CD(s)				
☐ Response to Missing Parts/ Incomplete Application	Remarks Non-Patent Literature Documents – 3 cited references				
☐ Response to Missing Parts under 37 CFR 1.52 or 1.53	Non Fatent Englature Boourneins 5	·			
SIGNATU	RE OF APPLICANT, ATTORNEY, OR A	AGENT			
Firm		· · · ·			
Or Ann M. Cannoni	•				
Signature	-				
Date April 12, 2007		,			
	·				

	CERTIFICATE OF TRANSMISSION/MAILING		
	espondence is being facsimile transmitted to the USPTO or deposited was mail in an envelope addressed to: Commissioner for Patents, P.O. B		
Typed or printed name	Melissa A. Wyke		
Signature	1 Lelisia A. Wike	Date	April 12, 2007
This collection of information is re	dured by 37 CFR 1.5. The information is required to obtain or retain a benefit by t	he public wi	nich is to file (and by the USPTO to

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application for the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Application No. 10/056,680 Filing Date: January 25, 2002 Paper Dated: April 12, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: T. Kosoglou et al.

Group Art Unit: 1617

Appl. No.: 10/056,680

Examiner: San-Ming R. Hui

Filed:

January 25, 2002

Case No.: CV01492K US

For:

Combinations of Sterol Absorption Inhibitor(s) with Blood Modifier(s) for Treating Vascular Conditions

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicant respectfully request that the following be considered and made of record, as well as the documents listed on the accompanying PTO Form SB/08A and SB/08B.

The commissioner is authorized to charge Deposit Account 23-0650 for any additional fees deemed necessary for consideration and entry of this Information Disclosure Statement into the file record.

record in the	isted on t e above-i sh transla	ant to the duty of disclosure under 37 C.F.R. §1.56, it is requested that the the accompanying Form SB/08A and SB/08B be considered and made of dentified patent application. Copy(ies) of these documents, along with a stion are enclosed were filed in related U.S. Application No(s) vely.
(b)	No fee	e is believed to be due because:
		This Information Disclosure Statement is being submitted concurrently with the filing of the above-identified application; or
		This Information Disclosure Statement is being submitted within three (3) months of the filing date of the above-identified application; or
		This Information Disclosure Statement is being submitted concurrently with a Request for Continued Examination (RCE); or
	\boxtimes	This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits.
(c)		This Information Disclosure Statement is being submitted before the mailing date of any final action, notice of allowance, or an action that otherwise closes prosecution; and:
		Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement: or

Application No. 10/056,680 Filing Date: January 25, 2002 Paper Dated: April 12, 2007

				No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; or
				The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
	(d)			formation Disclosure Statement is being submitted on or before the nt of the issue fee; and:
				Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
				No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; and
				The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
\boxtimes	require		is Inforr	hereby authorized to charge any additional fees which may be nation Disclosure Statement, or credit any overpayment to Deposit
				Respectfully submitted,
				THE WEBB LAW FIRM
700 Kc 436 Se Pittsbu Telepho Facsim	oppers Eventh Argh, Persone: 41	12, 2007 Building Evenue nnsylvan 12-471-8 2-471-4(law@we	nia 1521 815 094	

2

APR 1 6 2007 W

Sheet

PTO/SB/08A (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/056,680			
Filing Date	January 25, 2002			
First Named Inventor	T. Kosoglou et al.			
Art Unit	1617			
Examiner Name	San-Ming R. Hui et al.			
Attorney Docket Number	(CV01492K US) 4686-045551			

			U. S. PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ^{2 (ff known)}			rigures / typear	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	1	US-				
		US-				
	<u> </u>	US-				
		US-				
	-	US-				
		US-				
		US-				
		US-				
-	<u> </u>	US-				
		US-				
		US-				

		FORE	GN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ°
						<u> </u>
						┢
	 					⊬
						Т

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

APR 16 7007 DO

PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

7	e for form 1449/PTO			Complete if Known			
Substitut	e tor torn 1443/210			Application Number	10/056,680	4	
INFO	DRMATION	DIS	CLOSURE	Filing Date	January 25, 2002	•	
STA	STATEMENT BY APPLICANT		First Named Inventor	T. Kosoglou et al.			
	(Use as many she	oto oo m		Art Unit	1617		
	(Ose as many sne	eis as II	ecessary)	Examiner Name	San-Ming R. Hui		
Sheet	2	of	2	Attorney Docket Number	(CV01492K US) 4686-045551	7	

	NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
1	M.D. Mashkovsky, "Lekarstvennye sredstva", Moscow, 2001, part 1, pp. 455-466	
2	D.A. Charkevit'ch "farmacolgya", Moscow, publ. "Medicina", 1987, pp. 47-48	
3	V.G. Belikov, "Farmacvtit'cheskaya chimia", Moscow, publ. "Vysshaya shcola", 1993, vol. 1, pp. 43-47	
	1 2	No.1 the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. M.D. Mashkovsky, "Lekarstvennye sredstva", Moscow, 2001, part 1, pp. 455-466 D.A. Charkevit'ch "farmacolgya", Moscow, publ. "Medicina", 1987, pp. 47-48 V.G. Belikov, "Farmacvtit'cheskaya chimia", Moscow, publ. "Vysshaya"

Signature Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.